Abbott heart valve deteriorates faster than rival device, FDA says in notice

The U.S. Food and Drug Administration has warned healthcare professionals about the potential for Abbott’s Trifecta heart valves to deteriorate. Based on the published literature, the FDA is concerned that the rate of early deterioration may be higher for Trifecta than for other surgical aortic valve replacement (SAVR) devices such as Edwards Lifesciences’ Magna bioprosthesis.